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Pdr5, a member of the extensive ABC transporter superfamily, is representative of a clinically
relevant subgroup involved in pleiotropic drug resistance. Pdr5 and its homologues drive drug
efflux through uncoupled hydrolysis of nucleotides, enabling organisms such as baker’s yeast
and pathogenic fungi to survive in the presence of chemically diverse antifungal agents. Here,
we present the molecular structure of Pdr5 solved with single particle cryo-EM, revealing
details of an ATP-driven conformational cycle, which mechanically drives drug translocation
through an amphipathic channel, and a clamping switch within a conserved linker loop that
acts as a nucleotide sensor. One half of the transporter remains nearly invariant throughout
the cycle, while its partner undergoes changes that are transmitted across inter-domain
interfaces to support a peristaltic motion of the pumped molecule. The efflux model proposed
here rationalises the pleiotropic impact of Pdr5 and opens new avenues for the development
of effective antifungal compounds.
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The ATP-binding cassette (ABC) transporters comprise anextensive family of membrane transport proteins. Thesemachines, found in all domains of life, are the primary
source of active transport across the cell membrane and share a
common architecture of two pairs of domains: the transmem-
brane (TMD) and the nucleotide-binding domain (NBD)1. ATP
binding and hydrolysis by the NBDs energises the transport cycle
by driving conformational changes in the TMDs that enable
substrate passage across the bilayer.
ABC transporters recognise a wide range of substrates,
including nutrients and cell-wall components2,3. Many of the
transporters (especially in eukaryotes) export toxic compounds
from cells; indeed, overexpression of these proteins is a key
contributor to multi-drug resistance (MDR) phenotypes. In plant
and fungi, several efflux pumps involved in MDR are found
within the pleiotropic drug resistance (PDR) subfamily, whose
members confer resistance to structurally and functionally
unrelated drugs and xenobiotics2. Pdr5 is the founding member
of a full-length transporter subfamily within the G subfamily of
ABC transporters, which otherwise contains half-size transpor-
ters. The distinguishing features of the PDR transporters include
a structural repeat in which the NBD domain is at the N-terminus
of both pseudo-protomers, resulting in a reverse transmembrane
topology in comparison with other ABC transporters and similar
to half-size ABCG transporters. PDR proteins also harbour a
characteristic N-terminal extension of approximately 160–170
amino acid residues of unknown function3.
Since its discovery 30 years ago4, the ABC transporter Pdr5
from Saccharomyces cerevisiae has become an established and
widely studied model for PDR proteins in fungi that include
major pathogens5. Whilst its physiological substrate (or sub-
strates) is not known, Pdr5 was shown to transport a wide variety
of chemicals, including azoles, ionophores, antibiotics and other
xenobiotics6,7. Pdr5 homologues in Candida albicans contribute
to increased mortality in immune-compromised patients8,9 and
fungicide resistance of the plant pathogen Botrytis cinerea5,10.
ABC transporters share several signature motifs in the NBDs11.
Both NBDs contribute residues of these conserved motifs to form
two nucleotide-binding sites (NBSs) that bind and hydrolyse
ATP. In Pdr5, one of the NBS is catalytically active (NBS2), while
the other (NBS1) is inactive due to multiple substitutions in
crucial residues of all but one motif. While this asymmetry is
shared with many other ABC transporters (e.g., CFTR)12, the
PDR subfamily represents its most extreme case13. It is unclear
how ATPase-deficiency at this nucleotide-binding site supports
the transport process.
Despite three decades of extensive study of Pdr5 biochemistry,
the protein has evaded structural characterisation, leaving a
wealth of transport data mostly untapped. Taking advantage of
recent improvements in homogenous preparations of Pdr514
(Supplementary Fig. 1) and advances in single-particle electron
cryo-microscopy (cryo-EM) of membrane proteins15, we set
about to study the molecular architecture of the transporter and
obtain insight into its distinctive mechanism.
In this work, we report the cryo-EM structure of Pdr5 from S.
cerevisiae, providing details of the fold and conformation of a
representative of the extensive PDR subfamily. One distinguishing
feature revealed by our model is a conserved linker region located
near the non-catalytic NBS1 site, which acts as a nucleotide sensor.
Additionally, through our high-resolution structures of the protein
with a bound transport ligand in substrate-receiving, and in
substrate-releasing conformation, we visualise the translocation of
drugs from the cytoplasm to the cell exterior. Based on these
structural data and earlier functional studies, we propose a model
for asymmetric action and drug efflux in Pdr5.
Results and discussion
Pdr5 in detergent-free system can be imaged with high-
resolution cryo-EM. The membrane environment is critical for
the activity of highly allosteric transporters like Pdr5. Several
purification protocols have been developed that sustain mem-
brane proteins in a native membrane-like environment16–19. In
this study, we reconstituted Pdr5 in peptidiscs, which are short
amphipathic bi-helical peptides17 compatible with single-particle
cryo-EM20,21, after purification from S. cerevisiae cell membranes.
Reconstituted Pdr5 retained ATPase activity (Supplementary
Fig. 2). Compared to the detergent-solubilised state, the kinetic
parameter Vmax (72.8 ± 2.9 nmol min−1 mg−1) decreased 3-fold
and KM (0.65 ± 0.01 mM) increased 1.5-fold One possible expla-
nation is that the peptidisc belt, more rigid than the detergent
shell, interfered with the efficiency of ATP hydrolysis. This pre-
paration yielded homogenous particles readily visualised by
electron cryo-microscopy (Supplementary Fig. 2a, b). We col-
lected four datasets: apo Pdr5, Pdr5 with added ATP, Pdr5 with
added ATP and sodium orthovanadate (Vi), and Pdr5 with ATP
and transport substrate rhodamine 6 G (R6G)7,22,23. Vi is an
analogue of inorganic phosphate, and a potent inhibitor of
ATPases that traps ABC transporters in a transition-state con-
formation by mimicking the action of the γ-phosphate during
ATP hydrolysis24–27.
The 3D reconstruction of Pdr5 was carried out predominantly
in RELION28 (Supplementary Fig. 4) and yielded four near-
atomic resolution cryo-EM maps. The sample with Pdr5 alone
produced a map containing no nucleotide ligands, which we refer
to as the apo-Pdr5 state (Supplementary Fig. 3d). The Pdr5 sample
with added ATP yielded a map containing the hydrolysed
nucleotide ADP in the canonical and ATP in the inactive site,
called here ADP-Pdr5 (Supplementary Fig. 3f). The sample with
added ATP and R6G produced a map with the nucleotide
composition as above, but also with a bound substrate in the
transport cavity, called here R6G-Pdr5 (Supplementary Fig. 3i).
The orthovanadate dataset contained Pdr5 in a distinct state,
showing the vanadate-trapped hydrolytic intermediate and
termed AOV-Pdr5, with ATP in the inactive and ADP-VO43-
(or Vi) in the canonical site (Supplementary Fig. 3h). These maps
represent the two most distinct conformational states of Pdr5:
inward-facing (substrate-receiving) and outward-facing (sub-
strate-releasing).
The resolution of the maps ranged between 2.9 Å and 3.8 Å,
calculated using Fourier shell correlation29 (Supplementary
Fig. 3d, f, h, j and Supplementary Table 1), revealing well-
resolved side-chains of bulkier amino acid residues (Fig. 1e–f).
The quality of the maps enabled the majority (90% amino acid
residues) of the structure of this 170-kDa transporter to be traced
with certainty for all four states. Some of the external loops of the
NBD domains had unresolved features, most likely due to
flexibility (Supplementary Figs. 5, 6).
Pdr5 adopts the architecture of an asymmetric, full-size ABC
transporter. Pdr5 clearly adopts the fold of type II exporters30 or,
according to the newly suggested nomenclature for ABC trans-
porters, a type V fold31. The Pdr5 model (Fig. 1b) reveals a
pseudo-dimeric architecture, undoubtedly the result of gene
duplication5. The NBD domains of Pdr5 are structurally similar
to those of other members of the superfamily and comprise the
RecA-like32,33 and helical sub-domain (the bottom and top halves
of NBD1 in Fig. 1c). The NBD1 and NBD2 of Pdr5 are struc-
turally similar (Fig. 1c), sharing 27% sequence identity. NBD2 is
the more conserved of the two; together with the C-loop of
NBD1, it forms the composite canonical hydrolytic NBS2,
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whereas NBD1 and the C-loop of NBD2 cannot sustain ATP
hydrolysis as its NBS1 is degenerated13,34.
As with the NBDs, the TMDs of Pdr5 are pseudo-dimeric
(Fig. 1d). Each TMD contains five long α-helices that span the
lipid bilayer, a broken transmembrane α-helix that makes a near-
90° bend inside the membrane (TH5 in TMD1 and TH11 in
TMD2), and an N-terminal amphipathic α-helix that lies on the
membrane surface (TH1a and 7a) (Fig. 1d and Supplementary
Fig. 6). The latter two are also present in ABCG235 and ABCG5/
G830, the closest structurally characterised relatives of Pdr5
(Supplementary Table 2 and Fig. 2). We also compared Pdr5 with
other members of the ABCG subfamily, found in bacteria: Wzm-
Wzt36 and TarGH37. As shown in Fig. 2, the structural differences
are more prominent with the latter two proteins (see also:
Supplementary Table 2) emphasising that Pdr5 is more closely
related to the human ABCG subfamily. The space between TMD1
and TMD2 is the location of the substrate channel in ABC
transporters1,38. Two TMD α-helices are of particular importance
to transport: the so-called coupling helix (CpH) and connecting
helix (CnH)39. In Pdr5, the CpHs are in the cytoplasmic portion
of TH2 and TH8. The CnHs are the amphipathic helices TH1a
and TH7a of TMD1 and TMD2 (Fig. 1d and Supplementary
Fig. 6). These helices form the main site of the interaction
between the TMD and the NBD. In ABCG2, these are also pivot
points for the structural transition between the substrate-bound
(or nucleotide-free) and substrate-releasing (ATP-bound) con-
formations of the transporter35,39.
Pdr5 contains a nucleotide-sensing linker domain. One dis-
tinctive feature of Pdr5 is the linker domain (LD), situated
between the two halves of Pdr5 and composed of two distinct
stretches. One part (LD1) is made from a loop extrusion of 30
amino acid residues situated between the first two β-sheet strands
of NBD1; it also contains an amphipathic α-helix (H3) that rests
on the surface of the lipid bilayer (Fig. 1b–d, Supplementary Fig. 5
and Supplementary Fig. 6). The other part (LD2) is formed by a
polypeptide chain that links the C-terminus of TMD1 with the
N-terminus of NBD2 and is shaped like an arch that rises from
the surface of the bilayer, goes past the first stretch of the LD and
ends with a short α-helical fragment (H17) that is almost per-
pendicular to the long helix in the domain. The 44 residues
connecting the short helix H17 with the NBD2 could not be
resolved, due to flexibility (Fig. 1b–d, Supplementary Figs. 5, 6).
The base of the loop of the first stretch and the middle part of the
arch in the second stretch directly contact the degenerated ATP-
binding site in NBD1 (Figs. 1b, 3). In the apo-Pdr5, the arch of
the LD2 connecting the TMD1 and NBD2 is not as well defined
in the map, and the short helix H17 could not be resolved (Fig. 3).
This could indicate that ATP binding in the degenerated site has a
Fig. 1 Structural features of Pdr5. a Depicted here is the cryo-EM map of Pdr5 in inward-open conformation (ADP-Pdr5). The map is coloured according
to the domain organisation (see key). The grey transparent envelope surrounding the protein is a Gaussian-filtered (2σ) version of the same map, showing
the extent and shape of the peptidisc shell around Pdr5. b Atomic model of Pdr5 built and refined against the map, in cartoon representation. c Top view
(cytoplasmic side) of the nucleotide-binding domains of Pdr5, showing the position of the bound nucleotides. The linker domain is also depicted. d Side and
top views of the transmembrane domain of Pdr5 with α-helices shown schematically as cylinders and numbered sequentially (TH1a–12) from the
N-terminus (cf. Supplementary Fig. 5 and S6). This panel also includes the linker domain and its two helices H3 and H17. e, f Two portions of the ADP-Pdr5
cryo-EM map, showing the reconstructed volume around representative secondary structural features: e α-helices TH7b and TH8 of TMD1 domain and (f)
a β-sheet in NBD1 domain. Arrowheads point to amino acid residues that have been arbitrarily chosen for orientation purposes. Abbreviations: ECD,
extracellular domain; LD, linker domain; NBD, nucleotide-binding domain; TMD, transmembrane domain.
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stabilising effect on that part of the LD, possibly through the
contact of E804 with the ribose, as well as an electrostatic inter-
action of the Q801 side-chain with the triphosphate (at least in
ADP-Pdr5) (Fig. 3 and Supplementary Fig. 10). The unresolved
region of Pdr5 between the H17 helix and NBD2 contains a
ubiquitination site on K82540,41, but there is no indication yet of
other complex interactions in that part of the transporter.
Sequence alignment of the PDR family revealed that the linker
region contacting ATP contains a motif, highly conserved in the
PDR subfamily, with a consensus sequence MQKGEIL (Fig. 3)
and the glutamine corresponding to Q801 mentioned above. The
most highly conserved (95%) residue in the motif is the glutamate
(E804 in Pdr5); in all other cases, this residue is an aspartate. In
our structure, E804 contacts N1011 and, together with the two
hydrophobic residues I805 and L806, positions the arch of LD2
between the loop extension of LD1 and NBD2 (Fig. 3). In the
apo-Pdr5 structure, the residues of the conserved MQKGEIL
motif cannot be discerned in the density, indicating that the motif
plays a structural role, perhaps ensuring that the linker domain
becomes more conformationally rigid when a nucleotide is bound
in NBS1.
We sought to analyse the motif biochemically, through a
mutation study. We targeted residues Q801 to I805, changing the
sizes of the side-chains, their polarity, or charge (Supplementary
Fig. 7). Firstly, we assayed the resistance of these mutants against
four drugs (rhodamine 6G, ketoconazole, fluconazole, and
cycloheximide) (Supplementary Fig. 7). Certain mutants dis-
played increased sensitivity, albeit in a substrate-dependent
manner (Supplementary Table 3). Highly significant increases
in sensitivity were observed for Q801 mutations to A or V for
cycloheximide, simultaneously not showing any influence in the
case of ketoconazole and rhodamine 6 G, with some effect for the
valine mutation and fluconazole. For E804, mutation to A showed
a highly significant effect only in the case of fluconazole. Overall,
Fig. 2 Structural comparison of Pdr5 and related transporters. The panels show the superposition of Pdr5 and four related ABC transporters: a human
sterol transporter ABCG5/8 (PDB-ID: 5DO7), b human multi-drug transporter ABCG2 (PDB-ID: 6XVI), c bacterial O-antigen polysaccharide transporter
Wzm-Wzt (PDB-ID: 7K2T), d bacterial teichoic acid transporter TarGH (PDB-ID: 6JBH). The r.m.s.d. (root-mean-square deviations) of atomic positions in
the amino-acid backbone are, for ABCG5/8: 4.3 Å, ABCG2: 3.9 Å, Wzm-Wzt: 9.2 Å, TarGHL: 14 Å. See also: Supplementary Table 2.
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the drug resistance analysis of this conserved motif supports its
role as a crucial structural element in Pdr5, and the PDR family.
However, it also revealed a rather complex pattern that highly
depends on the nature of the drug.
The ATPase activity of these mutants was also analysed, using
plasma membrane vesicles (Supplementary Fig. 8). Pdr5-enriched
plasma membranes were selected over purified protein to ensure
retention of native lipid environment. To account for differences in
expression level or effective membrane insertion, Coomassie-
stained SDS-PAGE (Supplementary Fig. 8a) was analysed by
densitometry. To enable direct comparison, signal intensity of Pma1
(Plasma membrane ATPase 1) was used as internal control. Based
on this analysis, the difference between the expression of Pdr5 wild-
type and the mutants was below 10%, and thus it was not taken into
account in the quantitative analysis of the ATPase activity
(Supplementary Fig. 8b). Supplementary Table 4 summarises the
statistical analysis of the kinetic parameters. Whilst KM values of the
wild-type and the mutants were not significantly different, the Vmax
values of all mutants except I805S were highly significantly
(p < 0.0001) decreased. This suggests that the highly conserved
MQKGEIL motif not only senses the nucleotide in the degenerated
NBS1, but is also involved in communication with the active NBS1.
This scenario is reminiscent of the case of converting the degenerate
site of Pdr5 into an active site that completely abolished ATPase
activity13. Furthermore, it highlights that Pdr5 is an uncoupled
transporter, and that even at the reduced Vmax value, it is still
capable of conferring drug resistance.
Pdr5 contains a structurally unique extracellular domain. The
extracellular (or apical) domain of Pdr5 (labelled as ECD1 and
ECD2 on Fig. 1b) interrupts the TMDs just before their
C-terminal α-helices: TH6 and TH12 (Fig. 1b and Supplementary
Fig. 6). Most of the ECD is composed of structured loops, with
two short helices (ECD1-H16 and ECD2-H29) at the base of the
domain, and a slightly longer, distorted helix facing the extra-
cellular milieu (ECD2-H28). Each half of the ECDs contains
disulfide bridges (C722 and C742 in ECD1, and C1411 and
C1455 as well as C1427 and C1452 of ECD2), which are probably
involved in the stabilisation of the local fold. Interestingly, there is
no inter-domain disulfide bridge like that seen in ABCG235. In
our cryo-EM map, the backbone of the asparagine N734 in ECD1
is well resolved, and its side-chain has additional density that is
likely due to glycosylation (Supplementary Fig. 9), consistent with
mass spectrometry profiling42.
NBS1 of Pdr5 does not support ATP hydrolysis. A number of
important ABC transporters possess atypical NBS that have
greatly diminished or no hydrolytic abilities due to substitutions
of key residues in canonical motifs. In Saccharomyces sp. the three
major drug efflux pumps (Yor1, Snq2 and Pdr5) have an atypical
NBS alongside the canonical one. Endowing NBS1 of Pdr5 with
hydrolytic capabilities abolishes substrate transport13.
The non-catalytic site of Pdr5 differs from the canonical NBS2
in all but one of the conserved regions: the D-loop. The signature
motif of the PDR family of ABC transporters, VSGGE, is present
in NBD1, and correctly supplying the relevant amino acid
residues to perform hydrolysis in NBS2, when the domains come
together, as part of the catalytic cycle of ABC transporters. Vice
versa, the signature motif of NBD2, LNVEQ, is mutated
completely and does not complement NBS1 (Fig. 4). However,
perhaps the most consequential mutation is found in the Walker
Fig. 3 Structure of Pdr5 linker domain. Section of the Pdr5 structure
surrounding the linker domain is shown in cartoon representation. ATP in
the non-hydrolytic site and some of the conserved residues of the linker
domain are depicted in stick representation. The three panels represent
different states of Pdr5: (a) the inward-facing apo-Pdr5, (b) the inward-
facing ADP-Pdr5, (c) the outward-facing AOV-Pdr5. Abbreviations: LD,
linker domain; NBD, nucleotide-binding domain; TMD, transmembrane
domain.
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Fig. 4 Nucleotide and substrate binding to Pdr5. The panels illustrate the contacts between Pdr5 with (a–d) nucleotides and (e) rhodamine 6 G. Some of
the residues that are important for nucleotide binding and/or catalysis are highlighted and labelled (cf. Supplementary Fig. 10). The domain colouring
follows the scheme of the previous figure. a The catalytic site (NBS2) of Pdr5 in inward-facing conformation (ADP-Pdr5) with bound ADP. b The catalytic
site of outward-facing Pdr5 (AOV-Pdr5) in a vanadate-trapped state that mimics the intermediate step of hydrolysis with an ADP-orthovanadate molecule.
A co-ordinated magnesium ion is depicted as a green sphere. c The deviant, inactive site (NBS1) of Pdr5 in the inward-facing conformation (ADP-Pdr5),
showing the bound ATP. d The same site in the outward-facing conformation (AOV-Pdr5), The residues surrounding the nucleotide are at the
corresponding positions of the catalytic site. e Side view and cross-section of the transmembrane part of Pdr5 in inward-facing conformation (Pdr5-R6G).
Dotted line on the side-view denotes the position of the cross-section. The efflux substrate rhodamine 6G is bound in the entrance cavity between TMD1
and TMD2 . The cross-section of Pdr5 is coloured by hydrophobicity, from turquoise (hydrophilic) to tan (most hydrophobic), and electrostatic potential,
from red (negative) to blue (positive). Abbreviations: AOV, ADP-orthovanadate; R6G, rhodamine 6G; TMD, transmembrane domain.
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B motif of the deviant ATP-binding site. Where the canonical site
has a glutamate residue (E1036), the deviant has an asparagine
(N334) in the same position (Fig. 4c), with a tremendous impact
on its ATPase activity. As the glutamate of Walker B polarises a
water nucleophile in the catalytic site22, the hydrolysis of ATP
cannot be accelerated with the N334 substitution. In the
canonical sites of full-length transporters, a similar inhibitory
effect has been achieved by mutating the catalytic glutamate to
glutamine, which resembles the protonated form of glutamate
(formed upon polarising the water)43–45. The non-catalytic ATP-
binding site does not show the presence of a magnesium ion,
although in the case of AOV-Pdr5, the map resolution in the
region may prevent unambiguous assignment (Figs. 4c, 5).
NBS2 of Pdr5 is a canonical catalytic site of an ABC trans-
porter. The other nucleotide-binding site, NBS2, is a functional
catalytic centre, capable of ATP hydrolysis and endowed with the
canonical motifs that support enzymatic function5,13,22, including
the D-loop, which provides a crucial point of contact between the
two halves of the NBD dimer, coupling ATP hydrolysis, NBD
dimerisation, and substrate transport1,46.
Our structures of Pdr5 provide a glimpse into the catalytic site
of the transporter in two forms: with bound ADP (ADP-Pdr5)
and with an ADP-orthovanadate complex (AOV-Pdr5) (Fig. 4a–b
and Fig. 5a–b, respectively) in NBS2. The ADP-Pdr5 structure
was solved using Pdr5 samples with added ATP, indicating that
the majority of ATP was hydrolysed before flash-freezing in
Fig. 5 Cryo-EM maps around Pdr5 ligands. The panels show the details of the cryo-EM map surrounding (a–d) the nucleotides and (e) rhodamine 6G (cf.
Fig. 4 and Supplementary Fig. 10). The domain colouring follows the scheme of the previous figures. a The catalytic site (NBS2) of Pdr5 in inward-facing
conformation (ADP-Pdr5) with bound ADP. b The catalytic site of outward-facing Pdr5 (AOV-Pdr5) in a vanadate-trapped state that mimics the
intermediate step of hydrolysis with an ADP-orthovanadate molecule. Vanadium is shown as a grey sphere and co-ordinated magnesium ion is depicted as
a green sphere. c The deviant, inactive site (NBS1) of Pdr5 in the inward-facing conformation (ADP-Pdr5), showing the bound ATP. d The same site in the
outward-facing conformation (AOV-Pdr5).
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liquid ethane. It also suggests that in the post-hydrolysis stage
ADP remains bound to the catalytic site, making ADP-Pdr5 the
default resting state of the transporter in vivo. We were able to
mimic the hydrolysis transition state of the transporter using
orthovanadate. The nucleotides bind the catalytic pocket in a
manner similar to other ABC transporters, reflecting the high
conservation of this site27,35,39. Among residues that contact the
nucleotide found in characteristic motifs, of particular impor-
tance are: K911, T912 and T913 in Walker A, with the lysine
residue binding the terminal γ-phosphate of ATP; Q951 of the Q-
loop, co-ordinating the magnesium ion in the ADP-Vi complex;
E1036 of Walker B, mentioned before; H1068 of the H-loop,
which acts as a proton-shuttle in the catalytic pocket; and residues
R307 and E313 of the D-loop, which are part of NBD1 and bring
together the two NBDs upon binding of ATP (Fig. 4a–b;
Supplementary Fig. 10). Pdr5 can utilise other nucleotides to
fuel its transport activity14,47, and this can be rationalised by our
structures from the distribution of nucleotide contacts: the
nucleobase does not appear to directly interact with amino-acid
residues of the binding site (Supplementary Fig. 10).
Pdr5 substrate rhodamine 6G binds in the cleft between the
TMDs. We solved the molecular structure of Pdr5 with the ligand
R6G, a common organic dye. R6G is nestled between the two
TMDs, in the inward-facing conformation of Pdr5, with ADP in
the catalytic NBS and ATP in the deviant site (Fig. 4e). The
amino-acid residues surrounding the ligand do not change
positions considerably compared to the ADP-bound state (Sup-
plementary Fig. 10c). Because of this, we hypothesise that there is
no cross-talk between the substrate binding pocket and the rest of
the transporter in the inward-facing conformation, which could
be supported by the fact that Pdr5 is an uncoupled transporter22.
R6G occupies a cleft that is positioned between the halves of the
transmembrane portion of the transporter and is flanked by helices
TMD1-TH2 and -TH5a as well as TMD2-TH8 and -TH11a (Fig. 4e
cf. Fig. 1d). This includes residue S1360 which is known from
mutational studies to be involved in R6G binding48. The pocket
makes a large opening that reaches more than halfway down the
depth of the cell membrane and is accessible from the cytosol as
well as the inner leaflet of the lipid bilayer (Fig. 6a). The surface of
the pocket is a mixed hydrophobic/hydrophilic environment, with
the predominance of the former (Fig. 4e). The studied transport
substrates of Pdr5 include mostly lipophilic molecules, which seem
compatible with the pocket, although it has been shown that
substrate volume rather than lipophilicity is the major determinant
of transporter selectivity7,49. The entrance to the substrate cavity on
the side of the bilayer has a slight negative charge, opposite to the
positively charged R6G, whilst the cavity itself remains more neutral
electrostatically (Fig. 4e). The location of R6G in the cleft between
the TMDs is comparable to the positioning of substrates in other
multi-drug transporters, such as ABCG250,51 (Supplementary
Fig. 10d) or TmrAB27. This suggests that this pocket, a feature of
the inward-facing conformation of Pdr5, is the transporter’s
substrate entry cavity (Supplementary Fig. 11).
Vanadate-trapped Pdr5 adopts the outward-facing conforma-
tion. The apo-Pdr5, ADP-Pdr5, and R6G-Pdr5 are in inward-facing
conformations and are very similar (Supplementary Fig. 12a–b); the
differences are limited to small structural rearrangements around the
nucleotide-binding sites when ADP and ATP are present. Our model
of AOV-Pdr5, a product of vanadate-trapping of Pdr5, yielded a
structural model that is in the outward-facing conformation (Fig. 6,
Supplementary Fig. 12b and Supplementary Movie 1). ADP and Vi,
when bound in the canonical NBS1, and supported by the presence
of ATP in the deviant NBS1, cause dimerisation of the two NBDs.
Pdr5 thus follows a pattern that is almost universally conserved
amongst ABC transporters and other proteins that share a similar
fold1,11. However, the closure of the NBS around the nucleotide is
markedly asymmetrical in this transporter, occurring mainly through
the interaction of the nucleotide bound in NBS1 with the D-loop of
the NBD1. Between the inward- and outward-facing conformations,
measured as the change in the distance from Walker A to the sig-
nature motif, NBS1 closes by 11 Å, while NBS1 just by 3.8 Å. As in
other ABC transporters, the interaction and resultant dimerisation of
the NBDs cause a structural change in both the transmembrane and
extracellular domains, switching the transporter’s overall conforma-
tion from inward-facing to outward-facing (Fig. 6).
In the outward-facing conformation, the helices of the TMD1
and TMD2 tilt towards each other on the cytosolic side and
spread further apart on the extracellular side (Fig. 6b, Left).
Helices that line the substrate entry cavity (TMD1-TH2, -TH5a,
and TMD2-TH8, -TH11a) tighten around it, simultaneously
opening up on the extracellular side to reveal a cleft that joins up
with the newly expanded cavity between ECD1 and ECD2
(Fig. 6b, Right). The conformational state changes are also highly
asymmetric. NBD2, which contains the catalytic nucleotide-
binding site, performs a greater domain movement than NBD1,
which hosts the deviant site—such asymmetry of movement has
also been observed in the heterodimeric transporter TM287/
28852. Similarly, greatest conformational changes in the trans-
membrane region of Pdr5 involve TMD2, which is responsible for
the closure of the substrate cavity and the opening of the
extracellular part of the transporter, while TMD1 is compara-
tively invariant (Supplementary Fig. 12b). The single-site
hydrolysis is a simplification of the symmetric ABC transporter
system, in which two ATP molecules (one in each catalytic site)
are required to complete the transport cycle53.
The use of vanadate to mimic the transition state of nucleotide
hydrolysis allows the transporter to be captured in a state that
would otherwise be inaccessible due to the speed of
hydrolysis24–27. Various studies report a high degree of structural
similarity between the transition and the pre-hydrolytic states for
other ABC transporters, indicating that ATP binding and not
hydrolysis induce the conformational change in the transporter
from the inward-facing to the outward-facing state27,54–58. We
suspect that a similar effect is at play in Pdr5, but further work
would be needed to establish this. Also, the details of the substrate
passage through the channel between the TMDs remain to be
elucidated for Pdr5 (and indeed for other ABC transporters), but
we envisage it to be somewhat akin to a peristaltic action where
the closure of the entry channel on the cytoplasmic side pushes
the substrate towards the expanding exit channel (Supplementary
Movie 2). A similar mechanism has been suggested for other
members of the ABCG subfamily, such as ABCG239.
The access to both the entrance cavity and the exit channel is from
the membrane-cytosol and membrane-extracellular interface (Fig. 6
and Supplementary Fig. 11), which in principle can accommodate
substrates coming from and/or directed to a lipophilic or hydro-
phobic environment; this appears compatible with the amphipathic
character of reported Pdr5 substrates and implies that substrates are
not released into the extracellular space but rather into the outer
leaflet of the plasma membrane. The entrance and exit sites are
asymmetric in shape and surface properties, so that the probability of
entry from one site may be higher than from the other (Fig. 6). The
Pdr5 exit channel might also contain the equivalent of the leucine
gate found in ABCG2, which controls drug extrusion in that
protein59 (Supplementary Fig. 13).
ATP binding induces rearrangement in the N-terminal
extension of Pdr5. The N-terminal part of Pdr5 contains a
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stretch of some 120 amino-acid residues that precede the con-
served portion of the NBD domain and is characteristic of the
PDR subfamily. Mutagenesis data imply a role of this domain in
signalling to other cellular processes and/or trafficking. We
observe that the N-terminal extension contains two helices H1
and H2 connected by an unresolved region of 43 amino-acids
(Supplementary Fig. 5 and Supplementary Fig. 6). The two helices
are on the outside of NBD1 (top left of Fig. 1c; cf. Supplementary
Fig. 12d) and occupy well-defined positions in the inward-facing
state (ADP-Pdr5). In contrast to the rest of the NBD1, which
maintains its overall structure between the two states, a pro-
nounced structural change in the N-terminal extension is
observed with ATP binding and switch to the outward-facing
(AOV-Pdr5) conformation (Supplementary Fig. 12d). In the
outward-facing state, helix H1 appears to be disordered and is
displaced by a coupled movement of H2 and helix H15 (Sup-
plementary Fig. 12d). These conformational changes could sup-
port recognition to trigger downstream effector processes.
Drug efflux occurs as Pdr5 switches between two conforma-
tions. The structural models of Pdr5 in different nucleotide and
ligand states presented here suggest how efflux works (summarised
graphically in Fig. 7). In the resting state, Pdr5 adopts an inward-
facing conformation with the substrate entry channel open towards
the cytoplasm and inner leaflet of the membrane. In this state,
corresponding to our ADP-Pdr5 model, the transporter has an ADP
molecule in NBS2 and ATP in the deviant NBS1. On the basis of
cellular concentrations of ATP in S. cerevisiae (1.51 ± 0.32 mM60)
and the transporter’s KM for the nucleotide (1.7 to 1.9mM
in vivo12,44, 0.44 ± 0.05mM in vitro14), it seems likely that the apo
state may represent about 50% of the population. The other
Pdr5 states, which were prepared from samples with added ATP,
have the nucleotide bound in the non-catalytic, deviant binding site;
this would support earlier suggestions that ATP remains in the site
throughout the transport cycle34 under physiological conditions.
The substrate entry cavity of the inward-facing Pdr5 can receive
the efflux substrate, as evidenced by our structure of Pdr5 with R6G
(R6G-Pdr5). At this point, if ADP in the catalytic site is exchanged
for ATP, transport can occur. The binding of ATP induces a
structural change, which involves the transporter switching con-
formation from inward-facing to outward-facing, as exemplified by
our vanadate-trapped structure (AOV-Pdr5). This change involves
sealing off the substrate entry cavity and opening an exit channel on
the extracellular side of the transmembrane domain. The transport
substrate moves from the entrance cavity into the exit channel and is
released into the extracellular medium or outer leaflet. After the
nucleotide is hydrolysed, the transporter reverts to the inward-facing
conformation. In this state, ADP remains bound to the catalytic site,
and the substrate entry channel is re-opened. Thus, the transport
cycle of Pdr5 is completed, and the transporter can accept the next
molecule of the substrate.
Fig. 6 Conformational changes upon ATP binding. The two panels depict the molecular structure model of inward-facing (a) and outward-facing (b)
conformations of Pdr5 in cartoon representation, and as a solvent-excluded surface with its cross-section. a Shown is the Pdr5 in the post-hydrolytic state,
with ADP present in the catalytic site (ADP-Pdr5) and the transport channel open onto the cytoplasmic side. The position of the substrate entrance cavity
is indicated. b The Pdr5 in the vanadate-trapped, outward-facing state is depicted. The exit channel for the substrate, which opens onto the extracellular
side, is indicated as well. Abbreviations: ECD, extracellular domain; NBD, nucleotide-binding domain; TMD, transmembrane domain.
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Pdr5 structure can rationalise many observed mutational
phenotypes. Our structures can also provide the basis to explain
important functional mutants that can be found in the rich Pdr5
literature. We analysed a number of these mutants (Supplemen-
tary Table 5) and mapped them onto the inward-facing structure
of Pdr5 (Fig. 8). Mutations that inactivate the transporter, G905S
and G908S, are located in the Walker A motif of the active NBS1.
An exchange of the highly conserved Gly residues in P-loop
NTPases is a well-known example for the inactivation of these
enzymes, for example in Ras61. The other known mutations
within the NBD are also localised in conserved motives, such as
the Q-loops of NBD1 (E244Q) and NBD2 (Q951G), the X-loops
of NBD1 (G302D) and NBD2 (G1009C) and the D-loop of NBD2
(G1040D and D1042N). It is obvious that these mutations will
interfere with ATP binding/hydrolysis and/or NBD–NBD com-
munication, leading to changed phenotypes. Interestingly, G1009
interacts with I805 of the MKEGEIL motif via the backbone. A
mutation to Cys would thus abolish this interaction and interfere
with domain-domain communication in Pdr5 resulting in gen-
erally reduced drug resistance23.
Mutations within the TMD can be grouped into two categories.
The first category involves mutations of residues that are part of
the R6G binding site (S1360F) or its vicinity (S1368A and
T1391I). The other category comprises residues that have a more
Fig. 7 Transport cycle of Pdr5. The substrate (in this case, rhodamine 6G) enters the cavity between the transmembrane domains from the cytoplasmic
side when Pdr5 is in inward-facing conformation. ADP remaining in the catalytic site from the previous hydrolysis step is exchanged for ATP. ATP binding
triggers a conformation change in Pdr5 from inward- to outward-facing, whereby the substrate is pushed through the substrate channel and released into
the extracellular medium. Upon nucleotide hydrolysis, the transporter reverts to inward-facing conformation, ready to receive another molecule of
substrate. In cellular conditions, an ATP molecule remains bound to the inactive site throughout the cycle. The asymmetric nature of nucleotide hydrolysis
means that one half of Pdr5 makes a larger conformational move than the other. Abbreviations: ECD, extracellular domain; NBD, nucleotide-binding
domain; R6G, rhodamine 6G; TMD, transmembrane domain.
Fig. 8 Mapping of known mutations of Pdr5. Functional mutants of Pdr5 found in literature (see: Supplementary Table 5) are mapped onto the cartoon
representation of inward-facing Pdr5 structure (R6G-Pdr5). Front and back views are shown. Mutations are highlighted as coloured spheres centred on the
Cα of the residue, while the bound ligand, rhodamine 6G, is shown in sticks representation. Mutations that inactivate Pdr5 are labelled with green spheres,
those that confer or alter drug resistance with orange and cyan spheres, respectively. Those with other, different phenotypes (see: Supplementary Table 5)
are highlighted with magenta. Colour-coding of domains of Pdr5 is identical to Fig. 1 and used throughout.
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structural function: S558Y of TH2 for example interacts with and
positions the linker between TH11a and TH11b. S648 of TH4 is
located in a helical bundle with TH5c and TH6. The bulky Phe
residue in the S648F mutation likely disturbs the bundle
architecture. Similarly, Y1311 of TH9b is located in a cluster of
Tyr residues (1301, 1305, 106, and 1311) and a replacement with
Ser will destabilise the aromatic interaction, resulting in an altered
drug specificity. No structural explanation, however, can be
provided for the phenotypes of T257I and S1048V.
Besides providing context to past functional and biochemical
studies on Pdr5, this work presents the first molecular structure of
an ABC transporter from the PDR subfamily. Our models
illustrate the unique features of this group of proteins. Chief
amongst them is the dynamic linker domain. We were able to
assign a functional role to the linker and show how it can
complement the binding of ATP in the non-catalytic, degenerate
NBS—another characteristic of PDR transporters. We also show
how asymmetry in nucleotide hydrolysis is reflected in the
conformational cycle of the transporter. The first half of Pdr5
(NBD1-TMD1) stays relatively immobile compared to the
second, which contains the active, catalytic nucleotide site.
Between the two halves of the transporter lies the transport
channel, able to accommodate the wide chemical variety of
Pdr5 substrates. The asymmetry of PDR is reflected in its
structure again: the substrate channel contains a single exit site.
However, this paper provides more than just a static glimpse into
the Pdr5 function. Through our study of multiple conformational
states, we were able to propose a model of how this protein
actively pumps chemicals across the membrane, using ATP
hydrolysis. Pdr5 is an archetypal member of a unique subfamily
of proteins, but it is also, unmistakably, an ABC transporter, in
both function and structure.
Methods
Protein expression and purification. The protocol of Wagner et al.14 was used for
producing and purifying stable Pdr5 preparations from S. cerevisiae and is sum-
marised briefly here.
Histidine-tagged Pdr5 was purified from S. cerevisiae strain YRE100122 grown
in YPD medium at 30 °C. Cells were harvested by centrifugation at OD600= 3.5
and lysed with glass beads in buffer containing 50 mM Tris-HCl (pH= 8.0), 5 mM
EDTA and EDTA-free Protease Inhibitor Cocktail tablets (Roche AG, Basel,
Switzerland). Cell debris was removed by centrifugation (4 °C): twice at 1000 × g
for 5 min and once at 3000 × g. Cell membrane was pelleted from the resulting
supernatant by centrifugation at 20,000 × g for 40 min (4 °C). The cell membrane
pellet was resuspended in Buffer A: 50 mM Tris-HCl (pH= 7.8), 50 mM NaCl,
10% (w/v) glycerol and adjusted to 10 mgmL−1 total protein concentration. The
solubilisation of membrane proteins was achieved through the addition of 1% (w/v)
of trans-4-(trans-4′-alkylcyclohexyl)cyclohexyl-α-D-maltoside (trans-PCC-α-M;
Glycon Biochemicals, GmbH, Luckenwalde, Germany) and 1 h incubation at 4 °C,
with gentle stirring. Non-solubilised material was removed by centrifugation at
170,000 × g for 45 min (4 °C).
Pdr5 was separated from other proteins by immobilised metal ion affinity
chromatography (IMAC), using a HiTrap Chelating HP column (GE Healthcare,
Chicago, IL, USA) loaded with Zn2+ ions and equilibrated with low-histidine buffer:
50 mM Tris-HCl (pH= 7.8), 500mM NaCl, 10% (w/v) glycerol, 2.5 mM L-histidine,
0.003% w/v trans-PCC-α-M. The sample was loaded onto the column, washed, and
eluted with a concentration gradient of histidine (up to 100mM). Fractions of
IMAC eluate containing Pdr5 were pooled and concentrated using a Vivaspin 6
centrifugal concentrator unit (Sartorius AG, Göttingen, Germany) with a molecular
weight cut-off (MWCO) of 100 kDa. Concentrated protein was further purified
using size-exclusion chromatography (SEC) on a Superdex 200 10/300 GL (GE
Healthcare, Chicago, IL, USA) column containing 0.003% (w/v) trans-PCC-α-M.
Fractions of highest Pdr5 concentration (approx. 2.5 mg mL−1) from SEC were
selected for reconstitution into peptidiscs17. The peptidisc solution was prepared
from bulk lyophilised peptidisc (Peptidisc Biotech, Vancouver, BC, Canada)
dissolved in 20 mM Tris-HCl (pH= 8.0) to a final concentration of 10 mgmL−1.
Dissolved peptidisc was mixed with solubilised Pdr5 sample in 1:1 weight ratio
(1:38 molar ratio) and incubated for 30 min at room temperature. The mixture was
separated using SEC on a Superose 6 10/300 GL column (GE Healthcare, Chicago,
IL, USA) equilibrated with buffer containing 50 mM Tris-HCl (pH= 7.8), 100 mM
NaCl and no detergent. This step yielded homogenous Pdr5/peptidisc assemblies.
Liquid drug assay. Ketoconazole, fluconazole (Sigma-Aldrich Merck KGaA,
Darmstadt, Germany), rhodamine 6 G (Acros Organics, Fair Lawn, NJ, USA) and
cycloheximide (Honeywell Fluka Inc., Charlotte, NC, USA) were prepared as stock
solutions in dimethyl sulfoxide (DMSO, Acros Organics, Fair Lawn, NJ, USA) and
diluted in sterile water, as necessary. The assay was carried out in sterile 96-well
microtiter plates with 20 µL drug, 180 µL YPD medium and 50 µL of OD600 0.2
yeast culture. Plates were incubated at 30 oC for 48 h and OD600 was measured with
a microplate absorbance reader (Bio-Rad Laboratories Inc., Hercules, CA, USA).
ATPase measurements in Pdr5-enriched plasma membranes. Plasma mem-
branes were prepared, and ATPase activity was determined as described
previously22. Briefly, oligomycin (OM) sensitive ATPase activity of plasma mem-
brane fractions was measured by a colorimetric assay. Isolated plasma membranes
(0.1 or 0.2 µg per well) were incubated with 0.1–10 mM ATP, 5 mM MgCl2 in
300 mM Tris-glycine buffer (pH= 9.0) in a final volume of 100 µL. To reduce
background, 0.2 mM ammonium molybdate, 50 mM KNO3, and 10 mM NaN3
were added. In a control reaction, OM (20 µg mL−1) was added to the assay to
determine the OM-sensitive ATPase activity. After incubation at 30 oC for 20 min,
the reaction was stopped by adding 25 µL of the sample to 175 µL of ice-cold
40 mM H2SO4. The amount of released inorganic phosphate was determined by a
colorimetric assay, using Na2HPO4 as standard.
Statistical analysis. All experiments were performed in triplicates. Error bars in
figures represent mean ± standard error. Ordinary one-way ANOVA tests were
performed as part of the analysis. P-values are provided in the legends of the
corresponding figures and tables, respectively. Degrees of freedom were 18 (Sup-
plementary Fig. 7 and Supplementary Table 3) and between 29 and 34 (Supple-
mentary Fig. 8B and Supplementary Table 4). F values against the four drugs
analysed were 20.7 (cycloheximide), 37.1 (fluconazole), 9.4 (ketoconazole), and 3.4
(rhodamine 6G). In the case of the mutants of the linker domain, F value were
calculated to be 3.1 for KM and 19.8 for Vmax.
Cryo-EM sample preparation and data collection. To prepare the vanadate-
trapped state sample (AOV-Pdr5), Pdr5 resuspended in peptidiscs (1.5 mg mL−1)
was mixed with 2 mM of ATP and 2mM MgCl2, and incubated for 2 min. To this
solution, 200 µM of freshly prepared sodium orthovanadate (Na3VO4) was added
and incubated for further 2 min. In the case of the R6G-Pdr5 dataset, Pdr5 was
mixed with 2 mM of ATP, 2 mM MgCl2, and 100 µM of rhodamine 6 G solution in
water. In the case of the ADP-Pdr5, just 2 mM of ATP, 2 mM MgCl2 were added.
The samples were incubated for 20 min prior to grid freezing. No additives were
used to prepare the apo state sample. To improve the distribution of particles in
vitreous ice (Supplementary Fig. 3c), an aqueous solution of CHAPSO was added
to all the samples to final concentration 8 mM. The solution was mixed by
pipetting and used immediately in grid preparation. 3 µL of the sample mixture
were applied onto a Cu 300-mesh EM grid with R1.2/1.3 holey carbon support film
(Quantifoil Micro Tools GmbH, Großlöbichau, Germany) which had been glow-
discharged prior to use. The sample applied to the grid was vitrified in liquid
ethane at –180 °C using a Vitrobot Mark IV (Thermo Fischer Scientific Corp.,
Eindhoven, The Netherlands).
The grids were imaged using Titan Krios G3 TEM (Thermo Fischer Scientific
Corp., Eindhoven, The Netherlands) operated at liquid nitrogen temperature, 300-
kV accelerating voltage, and in EF-TEM mode with GIF slit size of 20 µm. The
micrographs were recorded using automated image acquisition software EPU
(Thermo Fischer Scientific Corp., Eindhoven, The Netherlands), in the case of the
ADP-Pdr5, R6G-Pdr5, and AOV-Pdr5 samples, on a K3 direct electron detector
(Gatan Inc., Pleasanton, CA, USA) in super-resolution counting mode, at a
detector pixel size of 0.326 Å (nominal magnification ×130,000) and nominal
defocus values between –0.7 and –2.2 µm. The micrographs of the apo-Pdr5 sample
were collected with a K2 Summit direct electron detector (Gatan Inc., Pleasanton,
CA, USA) in counting mode, at a detector pixel size of 1.07 Å (nominal
magnification ×130,000) at similar nominal defocus values. For the apo-Pdr5
sample, exposures lasted 12 s and were collected in 40 fractions (processing frames)
each, with total measured electron fluency of exposure was 58.1 e–Å−2. A total of
4,211 micrographs were acquired over the course of a single 72-h data collection
session. For the ADP-Pdr5 sample, the exposures lasted 1.31 s, collected in 49
fractions and fluency of 47.21 e–Å−2. This dataset contained 3,415 micrographs.
The R6G-Pdr5 and AOV-Pdr5 datasets were obtained using similar exposure
conditions, with fluencies of 47.73 and 48.13 e–Å−2; they amounted to 3604 and
8370 micrographs, respectively.
Cryo-EM data processing for structure solution. The cryo-EM map of apo-Pdr5
was reconstructed in RELION-3.028 and cryoSPARC-2.1562 (Supplementary
Fig. 4). Micrographs were corrected for beam-induced sample motion within
RELION. Contrast transfer function (CTF) parameters were estimated using Gctf-
1.0863 on non-dose-weighted micrograph averages. A subset of the images with
estimated maximum resolution below 4 Å was selected from the full dataset for
further processing. A manual pick of ca. 2000 particles was used to prepare a set of
2D references for automated particle search, which was subsequently optimised to
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yield diverse projections of Pdr5 particles. The initial particle pool was extracted in
320-pixel boxes and pruned through a series of reference-free 2D classification
rounds to 68,154. A model for cryo-EM reconstruction was created through sto-
chastic gradient descent (SGD) algorithm in RELION on 8,000 randomly selected
particles. The model and the pruned particle pool were subjected to 3D auto-
refinement, which generated the first intermediate cryo-EM map used for sub-
sequent Bayesian particle polishing and CTF refinement64.
To improve the quality of the protein part of the apo-Pdr5/peptidisc assembly
cryo-EM map, the density of the peptidisc was subtracted from the full map, using
tools and procedures implemented in RELION65,66. First, a mask template was
prepared by removing the Pdr5 part of the density from the full map, with the
Volume Eraser utility of UCSF Chimera-1.1367. Second, the template was
transformed into a binarised mask with a cosine-soft edge in RELION. The signal
from within the mask was subtracted from the particles in the full map set from the
last 3D auto-refinement step. The result of the subtraction was validated with 2D
classification of the subtracted particle set. The final map reconstruction was
performed on subtracted particles using non-uniform refinement (NU-refinement)
algorithm in cryoSPARC68. The overall resolution of the obtained map, as judged
by Fourier-shell correlation (FSC) of the half-maps with the gold-standard FSC0.143
criterion29, was 3.45 Å.
The cryo-EM maps from the ADP-Pdr5 and the rhodamine 6G R6G-Pdr5
datasets were processed similarly, although RELION-3.1 was used for the
reconstruction and corrected for high-order aberrations and anisotropic
magnification errors69. The raw micrographs were down-sampled by a factor of 2,
yielding an input set of images with an effective pixel size of 0.652 Å. Contrast
transfer function (CTF) parameters were estimated using CTFFIND-4.170 on non-
dose-weighted micrograph averages. The initial particle pool was extracted in 524-
pixel boxes and pruned through a series of 2D and 3D classification rounds. In the
case of the ADP-Pdr5 dataset, an improvement in the signal-to-noise ratio of the
protein part of the Pdr5/peptidisc assembly was achieved using SIDESPLITTER-
1.271 which locally de-noises cryo-EM maps72 and 3D map reconstructions were
done externally to RELION-3.1 between the iterative steps of 3D auto-refinement.
The overall resolution of the final maps obtained by the combined use of
SIDESPLITTER-1.2 and RELION-3.1 was 2.85 Å (ADP-Pdr5) and 3.13 Å (R6G-
Pdr5), per the FSC0.143 criterion.
The vanadate-trapped AOV-Pdr5 dataset was processed similarly to apo-Pdr5,
combining the use of RELION-3.1 and cryoSPARC-3.0. The raw micrographs were
down-sampled to an effective pixel size 0.652 Å. The initial particle pool was
extracted in 524-pixel boxes and pruned through a series of 2D and 3D
classification rounds. The overall resolution of the final map was 3.75 Å, per the
FSC0.143 criterion.
Model building and refinement. The reconstructed cryo-EM map of ADP-Pdr5
was used for de novo building of an atomic model of S. cerevisiae Pdr5. A pre-
liminary model was calculated using the Rosetta software suite73. The model was
adjusted manually in Coot-0.974, part of the CCP-EM package75, and in ISOLDE-
1.0b376. Model refinement was carried out in real space using PHENIX-1.18.277.
To assist model building, the maps were subjected to a density modification
procedure78, implemented as part of the PHENIX-1.18.2. Model building in high
flexibility regions of Pdr5 was facilitated through local map sharpening with
LocScale79, part of the CCP-EM-1.4.1 program suite75. Other models were built
manually, using the ADP-Pdr5 structure as a starting point. Locally sharpened
maps were also used for visualisation purposes. Molecular graphics were rendered
in ChimeraX-1.1380 and PyMOL-1.8.2.3 (Schrödinger LLC). All refinement and
data collection statistics are summarised in Supplementary Table 1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The molecular structure data generated in this study have been deposited in the PDB
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